Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 645

The DOI matches its Crossref record; 544 of the 544 references it cites were found in a registry or an index.

The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients

Open access
Velleca, Angela, Shullo, Michael A, Dhital, Kumud, Azeka, Estela, Colvin, Monica, DePasquale, Eugene, Farrero, Marta, García-Guereta, Luis, Jamero, Gina, Khush, Kiran, Lavee, Jacob, Pouch, Stephanie, Patel, Jignesh, Michaud, CJ, Shullo, Michael A, Schubert, Stephan, Angelini, Annalisa, Carlos, Lilibeth, Mirabet, Sonia, Patel, Jignesh, Pham, Michael, Urschel, Simon, Kim, Kyung-Hee, Miyamoto, Shelly, Chih, Sharon, Daly, Kevin, Grossi, Paolo, Jennings, Douglas L, Kim, In-cheol, Lim, Hoong Sern, Miller, Tara, Potena, Luciano, Velleca, Angela, Eisen, Howard, Bellumkonda, Lavanya, Danziger-Isakov, Lara, Dobbels, Fabienne, Harkess, Michelle, Kim, Daniel, Lyster, Haifa, Peled, Yael, Reinhardt, Zdenka·2023·The Journal of Heart and Lung Transplantation

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.healun.2022.10.015

Cites

544 of 544 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 544 references

Research works printed but not linked: 385

  1. Barge-Caballero, 2017, Prognostic value of the nutritional risk index in heart transplant recipients, Revis Española Cardio (English Edition), 70, 639, 10.1016/j.rec.2017.01.005 · doi:10.1016/j.rec.2017.01.005
  2. Crawford, 2020, Impact of the new pulmonary hypertension definition on heart transplant outcomes, Chest, 157, 151, 10.1016/j.chest.2019.07.028 · doi:10.1016/j.chest.2019.07.028
  3. Tsukashita, 2015, Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival, J Thorac Cardiovasc Surg, 150, 1352, 10.1016/j.jtcvs.2015.07.012 · doi:10.1016/j.jtcvs.2015.07.012
  4. Vakil, 2014, Impact of pre-transplant pulmonary hypertension on survival after heart transplantation: a UNOS registry analysis, Int J Cardiol, 176, 595, 10.1016/j.ijcard.2014.08.072 · doi:10.1016/j.ijcard.2014.08.072
  5. Koulova, 2017, Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation, J Thorac Dis, 9, 2640, 10.21037/jtd.2017.07.24 · doi:10.21037/jtd.2017.07.24
  6. Nagpal, 2017, Temporary mechanical circulatory support in cardiac critical care: a state of the art review and algorithm for device selection, Can J Cardiol, 33, 110
  7. Sánchez-Enrique, 2017, Heart transplant and mechanical circulatory support in patients with advanced heart failure, Rev Española Cardiol (English Edition), 70, 371, 10.1016/j.rec.2016.12.036 · doi:10.1016/j.rec.2016.12.036
  8. Chen, 2018, Prelisting predictions of early postoperative survival in infant heart transplantation using classification and regression tree analysis, Pediatr Transplant, 22, e13105, 10.1111/petr.13105 · doi:10.1111/petr.13105
  9. Peng, 2019, Risk factors for early and late mortality in pediatric heart transplantation, Pediatr Heart Transplant, 224
  10. Davies, 2014, Creation of a quantitative score to predict the need for mechanical support in children awaiting heart transplant, Ann Thorac Surg, 98, 675, 10.1016/j.athoracsur.2014.04.087 · doi:10.1016/j.athoracsur.2014.04.087
  11. Morales, 2019, Third annual pediatric interagency registry for mechanical circulatory support (pedimacs) report: preimplant characteristics and outcomes, Ann Thorac Surg, 107, 993, 10.1016/j.athoracsur.2019.01.038 · doi:10.1016/j.athoracsur.2019.01.038
  12. Yarlagadda, 2017, Temporary circulatory support in U.S. children awaiting heart transplantation, J Am Coll Cardiol, 70, 2250, 10.1016/j.jacc.2017.08.072 · doi:10.1016/j.jacc.2017.08.072
  13. Kubak, 2009, Use of hearts transplanted from donors with severe sepsis and infectious deaths, J Heart Lung Transplant, 28, 260, 10.1016/j.healun.2008.11.911 · doi:10.1016/j.healun.2008.11.911
  14. Wolfe, 2019, Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin Transplant, 33
  15. Ising, 2018, Changing demographics of heart donors: the impact of donor drug intoxication on posttransplant survival, Am J Transplant, 18, 1790, 10.1111/ajt.14726 · doi:10.1111/ajt.14726
  16. Jacob, 2015, Chronic alcoholic donors in heart transplantation: a mortality meta-analysis, Int J Cardiol, 191, 7, 10.1016/j.ijcard.2015.04.253 · doi:10.1016/j.ijcard.2015.04.253
  17. Taghavi, 2014, Use of heavy drinking donors in heart transplantation is not associated with worse short- and medium-term mortality, J Heart Lung Transplant, 33, S267, 10.1016/j.healun.2014.01.708 · doi:10.1016/j.healun.2014.01.708
  18. Warraich, 2017, Trends and outcomes of cardiac transplantation from donors dying of drug intoxication, J Card Fail, 23, S118, 10.1016/j.cardfail.2017.07.346 · doi:10.1016/j.cardfail.2017.07.346
  19. Martin-Suarez, 2008, Cardiac transplantation from a carbon monoxide intoxicated donor, Transplant Proc, 40, 1563, 10.1016/j.transproceed.2008.03.155 · doi:10.1016/j.transproceed.2008.03.155
  20. Sezgin, 2008, Successful cardiac transplantation from donor with carbon monoxide intoxication: a case report, Transplant Proc, 40, 324, 10.1016/j.transproceed.2007.11.061 · doi:10.1016/j.transproceed.2007.11.061
  21. Estevez-Loureiro, 2010, Prevalence of donor-transmitted coronary artery disease and its influence on heart transplant outcomes, Transplant Proc, 42, 2987, 10.1016/j.transproceed.2010.07.088 · doi:10.1016/j.transproceed.2010.07.088
  22. Kimura, 2018, Impact of coronary artery calcification in the donor heart on transmitted coronary artery disease in heart transplant recipients, Circ J, 82, 3021, 10.1253/circj.CJ-18-0107 · doi:10.1253/circj.cj-18-0107
  23. Pinto, 2013, Coronary artery bypass graft surgery during heart transplantation, Interactive CardioVascular and Thoracic Surgery, 16, 224, 10.1093/icvts/ivs432 · doi:10.1093/icvts/ivs432
  24. Patel, 2017, Bioprosthetic aortic valve replacement in a donor heart before orthotopic heart transplantation, Tex Heart Inst J, 44, 135, 10.14503/THIJ-16-5789 · doi:10.14503/thij-16-5789
  25. Pawale, 2012, Bench mitral valve repair of donor hearts before orthotopic heart transplantation, Circulation: Heart Fail, 5, 96
  26. Sprengel, 2018, Combined mitral valve repair and heart transplantation, Clin Case Rep, 6, 564, 10.1002/ccr3.1342 · doi:10.1002/ccr3.1342
  27. Sultan, 2018, Concomitant aortic valve replacement with orthotopic heart transplantation, J Thorac Cardiovasc Surg, 155, e151, 10.1016/j.jtcvs.2017.10.125 · doi:10.1016/j.jtcvs.2017.10.125
  28. Wever Pinzon, 2011, Impact of donor left ventricular hypertrophy on survival after heart transplant, Am J Transplant, 11, 2755, 10.1111/j.1600-6143.2011.03744.x · doi:10.1111/j.1600-6143.2011.03744.x
  29. Chen, 2017, Low ejection fraction in donor hearts is not directly associated with increased recipient mortality, J Heart Lung Transplant, 36, 611, 10.1016/j.healun.2017.02.001 · doi:10.1016/j.healun.2017.02.001
  30. Sibona, 2019, Long-term transplant outcomes of donor hearts with left ventricular dysfunction, J Thorac Cardiovasc Surg, 157, 1865, 10.1016/j.jtcvs.2018.07.115 · doi:10.1016/j.jtcvs.2018.07.115
  31. Chew, 2019, Outcomes of donation after circulatory death heart transplantation in Australia, J Am Coll Cardiol, 73, 1447, 10.1016/j.jacc.2018.12.067 · doi:10.1016/j.jacc.2018.12.067
  32. Messer, 2017, Outcome after heart transplantation from donation after circulatory-determined death donors, J Heart Lung Transplant, 36, 1311, 10.1016/j.healun.2017.10.021 · doi:10.1016/j.healun.2017.10.021
  33. Nyawo, 2008, The effect of a large proximal haemodialysis arterio-venous fistula on weaning off cardiopulmonary bypass: case report, J Cardiothorac Surg, 3, 44, 10.1186/1749-8090-3-44 · doi:10.1186/1749-8090-3-44
  34. Awad, 2017, Combined heart and kidney transplantation: a 23-year experience, Transplant Proc, 49, 348, 10.1016/j.transproceed.2016.11.040 · doi:10.1016/j.transproceed.2016.11.040
  35. Chou, 2019, Heart-kidney and heart-liver transplantation provide immunoprotection to the cardiac allograft, Ann Thorac Surg, 108, 458, 10.1016/j.athoracsur.2019.02.012 · doi:10.1016/j.athoracsur.2019.02.012
  36. Nagpal, 2013, Combined heart and liver transplantation: the cleveland clinic experience, Ann Thorac Surg, 95, 179, 10.1016/j.athoracsur.2012.09.010 · doi:10.1016/j.athoracsur.2012.09.010
  37. Healy, 2013, Impact of ventricular assist device complications on posttransplant survival: an analysis of the united network of organ sharing database, Ann Thorac Surg, 95, 870, 10.1016/j.athoracsur.2012.10.080 · doi:10.1016/j.athoracsur.2012.10.080
  38. Healy, 2016, Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices—an analysis of the International Society for Heart and Lung Transplantation Transplant Registry, J Heart Lung Transplant, 35, 34, 10.1016/j.healun.2015.07.007 · doi:10.1016/j.healun.2015.07.007
  39. Bozzetti, 2008, Concomitant pulmonary hypertension and vasoplegia syndrome after heart transplant: a challenging picture, J Cardiothorac Vasc Anesth, 22, 868, 10.1053/j.jvca.2007.11.003 · doi:10.1053/j.jvca.2007.11.003
  40. Truby, 2018, Incidence and impact of on-cardiopulmonary bypass vasoplegia during heart transplantation, ASAIO J, 64, 43, 10.1097/MAT.0000000000000623 · doi:10.1097/mat.0000000000000623
  41. Lee, 2016, Prothrombin complex concentrate and methylene blue for treatment of coagulopathy and vasoplegia in a pediatric heart transplant patient, A Case Reports, 6, 127, 10.1213/XAA.0000000000000271 · doi:10.1213/xaa.0000000000000271
  42. Raza, 2018, Relation of vasoplegia in the absence of primary graft dysfunction to mortality following cardiac transplantation, Am J Cardiol, 122, 1902, 10.1016/j.amjcard.2018.08.035 · doi:10.1016/j.amjcard.2018.08.035
  43. Zundel, 2016, Use of oral droxidopa to improve arterial pressure and reduce vasoactive drug requirements during persistent vasoplegic syndrome after cardiac transplantation, J Cardiothorac Vasc Anesth, 30, 1624, 10.1053/j.jvca.2015.12.013 · doi:10.1053/j.jvca.2015.12.013
  44. Kieler-Jensen, 1995, Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside, J Heart Lung Transplant, 14, 436
  45. McGinn, 2016, A comparison of inhaled nitric oxide versus inhaled epoprostenol for acute pulmonary hypertension following cardiac surgery, Ann Pharmacother, 50, 22, 10.1177/1060028015608865 · doi:10.1177/1060028015608865
  46. Rao, 2018, Inhaled nitric oxide (iNO) and inhaled epoprostenol (iPGI 2) use in cardiothoracic surgical patients: is there sufficient evidence for evidence-based recommendations?, J Cardiothorac Vasc Anesth, 32, 1452, 10.1053/j.jvca.2017.12.014 · doi:10.1053/j.jvca.2017.12.014
  47. Torbic, 2013, Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients, J Crit Care, 28, 844, 10.1016/j.jcrc.2013.03.006 · doi:10.1016/j.jcrc.2013.03.006
  48. Ahmari, 2006, Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter, J Heart Lung Transplant, 25, 53, 10.1016/j.healun.2005.07.017 · doi:10.1016/j.healun.2005.07.017
  49. Nof, 2013, Catheter ablation of atrial arrhythmias after cardiac transplantation: findings at EP study utility of 3-D mapping and outcomes: catheter ablation of atrial arrhythmias, J Cardiovasc Electrophysiol, 24, 498, 10.1111/jce.12078 · doi:10.1111/jce.12078
  50. Schumacher, 2011, Postoperative care of the transplanted patient, Curr Cardiol Rev, 7, 110, 10.2174/157340311797484286 · doi:10.2174/157340311797484286
  51. Holzhauser, 2018, Consequences of retained defibrillator and pacemaker leads after heart transplantation—an underrecognized problem, J Card Fail, 24, 101, 10.1016/j.cardfail.2017.12.012 · doi:10.1016/j.cardfail.2017.12.012
  52. Albatati, 2020, Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients, Pediatr Res, 87, 892, 10.1038/s41390-019-0523-4 · doi:10.1038/s41390-019-0523-4
  53. Manlhiot, 2010, Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients, J Heart Lung Transplant, 29, 648, 10.1016/j.healun.2010.01.013 · doi:10.1016/j.healun.2010.01.013
  54. Schubert, 2008, Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant Patients, J Heart Lung Transplant, 27, 100, 10.1016/j.healun.2007.09.027 · doi:10.1016/j.healun.2007.09.027
  55. Abdala, 2018, Endemic fungal infection recommendations for solid-organ transplant recipients and donors, Transplantation, 102, S52, 10.1097/TP.0000000000002020 · doi:10.1097/tp.0000000000002020
  56. Grossi, 1993, Pneumocystis carinii pneumonia in heart transplant recipients, Infection, 21, 75, 10.1007/BF01710735 · doi:10.1007/bf01710735
  57. Hall, 1993, Coccidioidomycosis and heart transplantation, J Heart Lung Transplant, 12, 525
  58. Hosseini-Moghaddam, 2019, A multicenter case-control study of the effect of acute rejection and cytomegalovirus infection on pneumocystis pneumonia in solid organ transplant recipients, Clin Infect Dis, 68, 1320, 10.1093/cid/ciy682 · doi:10.1093/cid/ciy682
  59. La Hoz RM, Morris MI. Transplantation tIDCoPotASo, Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients— guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:1-20. · doi:10.1111/ctr.13546
  60. Ng, 2011, Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients: pediatric outcomes of Pneumocystis jiroveci pneumonia, Pediatr Transplant, 15, 844, 10.1111/j.1399-3046.2011.01589.x · doi:10.1111/j.1399-3046.2011.01589.x
  61. Saxena, 2018, Invasive fungal disease in pediatric solid organ transplant recipients, J Pediatr Infect Dis Soc, 7, 219, 10.1093/jpids/pix041 · doi:10.1093/jpids/pix041
  62. Berg, 2017, Mortality risk stratification in fontan patients who underwent heart transplantation, Am J Cardiol, 119, 1675, 10.1016/j.amjcard.2017.02.005 · doi:10.1016/j.amjcard.2017.02.005
  63. Gokanapudy, 2019, Heart transplantation for the failed fontan, Pediatric heart transplantation, 28
  64. Schleiger, 2020, Treatment strategies for protein-losing enteropathy in Fontan-palliated patients, Cardiol Young, 30, 698, 10.1017/S1047951120000864 · doi:10.1017/s1047951120000864
  65. Schumacher, 2019, Fontan-associated protein-losing enteropathy and post‒heart transplant outcomes: a multicenter study, J Heart Lung Transplant, 38, 17, 10.1016/j.healun.2018.09.024 · doi:10.1016/j.healun.2018.09.024
  66. Dori, 2013, Acute effects of embolizing systemic-to-pulmonary arterial collaterals on blood flow in patients with superior cavopulmonary connections: a pilot study, Circ Cardiovasc Interv, 6, 101, 10.1161/CIRCINTERVENTIONS.112.972265 · doi:10.1161/circinterventions.112.972265
  67. Krishnan, 2004, Management of aortopulmonary collaterals in children following cardiac transplantation for complex congenital heart disease, J Heart Lung Transplant, 23, 564, 10.1016/S1053-2498(03)00305-X · doi:10.1016/s1053-2498(03)00305-x
  68. Kobashigawa, 2018, The management of antibodies in heart transplantation: an ISHLT consensus document, J Heart Lung Transplant, 37, 537, 10.1016/j.healun.2018.01.1291 · doi:10.1016/j.healun.2018.01.1291
  69. Ko, 2016, Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant, J Heart Lung Transplant, 35, 1024, 10.1016/j.healun.2016.05.001 · doi:10.1016/j.healun.2016.05.001
  70. Reinsmoen, 2016, Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens, J Heart Lung Transplant, 35, 165, 10.1016/j.healun.2015.10.013 · doi:10.1016/j.healun.2015.10.013
  71. Laing, 2010, Glutaraldehyde treatment of allograft tissue decreases allosensitization after the Norwood procedure, J Thorac Cardiovasc Surg, 139, 1402, 10.1016/j.jtcvs.2009.12.034 · doi:10.1016/j.jtcvs.2009.12.034
  72. Mahle, 2011, Allosensitization and outcomes in pediatric heart transplantation, J Heart Lung Transplant, 30, 1221, 10.1016/j.healun.2011.06.005 · doi:10.1016/j.healun.2011.06.005
  73. Meyer, 2005, Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation, Eur J Cardiothorac Surg, 27, 554, 10.1016/j.ejcts.2004.12.033 · doi:10.1016/j.ejcts.2004.12.033
  74. Patel, 2021, Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients, Am J Transplant, 21, 2479, 10.1111/ajt.16420 · doi:10.1111/ajt.16420
  75. Foreman, 2004, ABO-incompatible heart transplantation: a perfusion strategy, Perfusion, 19, 69, 10.1191/0267659104pf708oa · doi:10.1191/0267659104pf708oa
  76. Urschel, 2013, ABO-incompatible heart transplantation in early childhood: an international multicenter study of clinical experiences and limits, J Heart Lung Transplant, 32, 285, 10.1016/j.healun.2012.11.022 · doi:10.1016/j.healun.2012.11.022
  77. Urschel, 2020, A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation, J Heart Lung Transplant, 39, 627, 10.1016/j.healun.2020.02.008 · doi:10.1016/j.healun.2020.02.008
  78. Profita, 2019, Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients, J Heart Lung Transplant, 38, 601, 10.1016/j.healun.2019.01.1310 · doi:10.1016/j.healun.2019.01.1310
  79. Simmonds, 2015, Predictors and outcome of extracorporeal life support after pediatric heart transplantation, Ann Thorac Surg, 99, 2166, 10.1016/j.athoracsur.2015.02.047 · doi:10.1016/j.athoracsur.2015.02.047
  80. Irving, 2015, ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers, J Heart Lung Transplant, 34, 1095, 10.1016/j.healun.2015.03.013 · doi:10.1016/j.healun.2015.03.013
  81. Jeyakanthan, 2012, Donor-specific isohemagglutinins: measuring the unknown: isohemagglutinins: measuring the unknown, Am J Transplant, 12, 803, 10.1111/j.1600-6143.2011.03913.x · doi:10.1111/j.1600-6143.2011.03913.x
  82. AuBuchon, 2008, Reducing the variation in performance of antibody titrations, Arch Pathol Lab Med, 132, 1194, 10.5858/2008-132-1194-RTVIPO · doi:10.5858/2008-132-1194-rtvipo
  83. Dean, 2018, Current state of transfusion practices for ABO-incompatible pediatric heart transplant patients in the United States and Canada: PEDIATRIC ABOiHT TRANSFUSION SUPPORT, Transfusion (Paris), 58, 2243, 10.1111/trf.14775 · doi:10.1111/trf.14775
  84. Robertson, 2018, A novel method for ABO-incompatible heart transplantation, J Heart Lung Transplant, 37, 451, 10.1016/j.healun.2017.05.006 · DOI
  85. Breuer, 2013, Management of cardiac surgery patients with Heparin-Induced Thrombocytopenia (HIT-II): experience with preoperative plasmaphereses plus intraoperative heparin, Eur Heart J, 34, 10.1093/eurheartj/eht310.P4888 · doi:10.1093/eurheartj/eht310.p4888
  86. Dalal, 2016, Organ transplantation and drug eluting stents: perioperative challenges, World J Transplant, 6, 620, 10.5500/wjt.v6.i4.620 · doi:10.5500/wjt.v6.i4.620
  87. Hollis, 2016, Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation, Ann Cardiac Anaesth, 19, 418, 10.4103/0971-9784.185523 · doi:10.4103/0971-9784.185523
  88. Loforte, 2019, Heart transplant and hepato-renal dysfunction: the model of end-stage liver disease excluding international normalized ratio as a predictor of postoperative outcomes, Transplant Proc, 51, 2962, 10.1016/j.transproceed.2019.07.013 · doi:10.1016/j.transproceed.2019.07.013
  89. Moretz, 2019, Anticoagulation reversal and risk of thromboembolic events among heart transplant recipients bridged with durable mechanical circulatory support devices, ASAIO J, 65, 649, 10.1097/MAT.0000000000000866 · doi:10.1097/mat.0000000000000866
  90. Pishko, 2017, Heparin-induced thrombocytopenia in cardiac surgery patients, Semin Thromb Hemost, 43, 691, 10.1055/s-0037-1602664 · doi:10.1055/s-0037-1602664
  91. Shore-Lesserson, 2018, STS/SCA/AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass, J Extra Corpor Technol, 50, 5, 10.1051/ject/201850005 · doi:10.1051/ject/201850005
  92. Wanek, 2019, Prothrombin complex concentrates for warfarin reversal before heart transplantation, Ann Thorac Surg, 107, 1409, 10.1016/j.athoracsur.2018.10.032 · doi:10.1016/j.athoracsur.2018.10.032
  93. Wu, 2018, Impact of prothrombin complex concentrate on blood use, cost, and outcomes in heart transplantation, Ann Thorac Surg, 105, 1152, 10.1016/j.athoracsur.2017.10.044 · doi:10.1016/j.athoracsur.2017.10.044
  94. Kaushal, 2014, A multicenter study of primary graft failure after infant heart transplantation: impact of extracorporeal membrane oxygenation on outcomes, Pediatr Transplant, 18, 72, 10.1111/petr.12181 · doi:10.1111/petr.12181
  95. Lima, 2015, Experience of ECMO in primary graft dysfunction after orthotopic heart transplantation, Arq Bras Cardiol, 105, 285
  96. Su, 2015, Extracorporeal membrane oxygenation support after pediatric orthotopic heart transplantation, Pediatr Transplant, 19, 68, 10.1111/petr.12382 · doi:10.1111/petr.12382
  97. Colvin, 2015, Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association, Circulation, 131, 1608, 10.1161/CIR.0000000000000093 · DOI · Paper page
  98. Everitt, 2012, Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant, J Heart Lung Transplant, 31, 686, 10.1016/j.healun.2012.03.009 · doi:10.1016/j.healun.2012.03.009
  99. Loupy, 2011, Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy, Am J Transplant, 11, 1478, 10.1111/j.1600-6143.2011.03563.x · doi:10.1111/j.1600-6143.2011.03563.x
  100. Thrush, 2016, A multi-institutional evaluation of antibody-mediated rejection utilizing the Pediatric Heart Transplant Study database: incidence, therapies and outcomes, J Heart Lung Transplant, 35, 1497, 10.1016/j.healun.2016.06.014 · doi:10.1016/j.healun.2016.06.014
  101. Kfoury, 2016, Mixed cellular and antibody-mediated rejection in heart transplantation: in-depth pathologic and clinical observations, J Heart Lung Transplant, 35, 335, 10.1016/j.healun.2015.10.016 · doi:10.1016/j.healun.2015.10.016
  102. Crespo-Leiro, 2012, Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II), Transplantation, 94, 1172, 10.1097/TP.0b013e31826e19e2 · doi:10.1097/tp.0b013e31826e19e2
  103. Lim, 2019, International Society of Heart and Lung Transplantation position statement on the role of right heart catheterization in the management of heart transplant recipients, J Heart Lung Transplant, 38, 235, 10.1016/j.healun.2018.12.009 · doi:10.1016/j.healun.2018.12.009
  104. Lammers, 2010, Acute rejection after paediatric heart transplantation: far less common and less severe, Transpl Int, 23, 38, 10.1111/j.1432-2277.2009.00941.x · doi:10.1111/j.1432-2277.2009.00941.x
  105. Zinn, 2017, Impact of age on incidence and prevalence of moderate-to-severe cellular rejection detected by routine surveillance biopsy in pediatric heart transplantation, J Heart Lung Transplant, 36, 451, 10.1016/j.healun.2016.09.017 · doi:10.1016/j.healun.2016.09.017
  106. Daly, 2012, Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience, J Heart Lung Transplant, 31, 398, 10.1016/j.healun.2011.11.019 · doi:10.1016/j.healun.2011.11.019
  107. Godown, 2015, Variation in the use of surveillance endomyocardial biopsy among pediatric heart transplant centers over time, Pediatr Transplant, 19, 612, 10.1111/petr.12518 · doi:10.1111/petr.12518
  108. Zinn, 2018, Impact of routine surveillance biopsy intensity on the diagnosis of moderate to severe cellular rejection and survival after pediatric heart transplantation, Pediatr Transplant, 22, e13131, 10.1111/petr.13131 · doi:10.1111/petr.13131
  109. Fitzsimons, 2018, Utility of troponin assays for exclusion of acute cellular rejection after heart transplantation: a systematic review, J Heart Lung Transplant, 37, 631, 10.1016/j.healun.2017.12.008 · doi:10.1016/j.healun.2017.12.008
  110. Patel, 2014, High-sensitivity cardiac troponin I assay to screen for acute rejection in patients with heart transplant, Circ Heart Fail, 7, 463, 10.1161/CIRCHEARTFAILURE.113.000697 · doi:10.1161/circheartfailure.113.000697
  111. Arnau-Vives, 2004, Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection, J Heart Lung Transplant, 23, 850, 10.1016/j.healun.2003.08.005 · doi:10.1016/j.healun.2003.08.005
  112. Garrido, 2009, Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation, Am J Cardiol, 103, 1149, 10.1016/j.amjcard.2009.01.008 · doi:10.1016/j.amjcard.2009.01.008
  113. Crespo-Leiro, 2016, Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II, Eur Heart J, 37, 2591, 10.1093/eurheartj/ehv682 · DOI
  114. Feingold, 2021, Early findings after integration of donor-derived cell-free DNA into clinical care following pediatric heart transplantation, Pediatr Transplant, e14124
  115. Kobashigawa, 2010, Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes, J Heart Lung Transplant, 29, 504, 10.1016/j.healun.2009.12.015 · doi:10.1016/j.healun.2009.12.015
  116. Clerkin, 2017, Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation, J Heart Lung Transplant, 36, 540, 10.1016/j.healun.2016.10.016 · doi:10.1016/j.healun.2016.10.016
  117. Ho, 2011, Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival, Hum Immunol, 72, 5, 10.1016/j.humimm.2010.10.013 · doi:10.1016/j.humimm.2010.10.013
  118. Irving, 2015, Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation, J Heart Lung Transplant, 34, 1310, 10.1016/j.healun.2015.05.001 · doi:10.1016/j.healun.2015.05.001
  119. Simsek, 2015, Diagnostic performance of late gadolinium enhancement in the assessment of acute cellular rejection after heart transplantation, Anatol J Cardiol, 16, 113
  120. Imran, 2019, Native T1 mapping in the diagnosis of cardiac allograft rejection, JACC: Cardiovasc Imaging, 12, 1618
  121. Feingold, 2017, Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: correlation of histology, cardiovascular magnetic resonance, and clinical phenotype, Pediatr Transplant, 21, 1, 10.1111/petr.12986 · doi:10.1111/petr.12986
  122. Bonnemains, 2015, Design of the DRAGET Study: a multicentre controlled diagnostic study to assess the detection of acute rejection in patients with heart transplant by means of T 2 quantification with MRI in comparison to myocardial biopsies, BMJ Open, 5, 10.1136/bmjopen-2015-008963 · doi:10.1136/bmjopen-2015-008963
  123. Butler, 2015, Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection, J Heart Lung Transplant, 34, 643, 10.1016/j.healun.2014.12.020 · doi:10.1016/j.healun.2014.12.020
  124. Dolan, 2019, Multiparametric cardiac magnetic resonance imaging can detect acute cardiac allograft rejection after heart transplantation, JACC: Cardiovasc Imaging, 12, 1632
  125. Evers, 2019, Outcomes of low-intensity biopsy surveillance for rejection in paediatric cardiac transplantation, Cardiol Young, 29, 910, 10.1017/S1047951119001112 · doi:10.1017/s1047951119001112
  126. Kindel, 2015, Improved detection of cardiac allograft vasculopathy: a multi-institutional analysis of functional parameters in pediatric heart transplant recipients, J Am Coll Cardiol, 66, 547, 10.1016/j.jacc.2015.05.063 · doi:10.1016/j.jacc.2015.05.063
  127. Mingo-Santos, 2015, Usefulness of two-dimensional strain parameters to diagnose acute rejection after heart transplantation, J Am Soc Echocardiogr, 28, 1149, 10.1016/j.echo.2015.06.005 · doi:10.1016/j.echo.2015.06.005
  128. Hernandez, 2015, Global left ventricular relaxation: a novel tissue Doppler index of acute rejection in pediatric heart transplantation, J Heart Lung Transplant, 34, 1190, 10.1016/j.healun.2015.03.027 · doi:10.1016/j.healun.2015.03.027
  129. Schmoeckel, 2005, Successful ABO-incompatible heart transplantation in two infants, Transpl Int, 18, 1210, 10.1111/j.1432-2277.2005.00181.x · doi:10.1111/j.1432-2277.2005.00181.x
  130. Almond, 2010, Impact of ABO-Incompatible listing on wait-list outcomes among infants listed for heart transplantation in the United States: a propensity analysis, Circulation, 121, 1926, 10.1161/CIRCULATIONAHA.109.885756 · doi:10.1161/circulationaha.109.885756
  131. Dipchand, 2010, Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible, Am J Transplant, 10, 389, 10.1111/j.1600-6143.2009.02934.x · doi:10.1111/j.1600-6143.2009.02934.x
  132. Henderson, 2012, ABO-incompatible heart transplantation: analysis of the Pediatric Heart Transplant Study (PHTS) database, J Heart Lung Transplant, 31, 173, 10.1016/j.healun.2011.11.013 · doi:10.1016/j.healun.2011.11.013
  133. Tydén, 2012, Intentional ABO-incompatible heart transplantation: a case report of 2 adult patients, J Heart Lung Transplant, 31, 1307, 10.1016/j.healun.2012.09.011 · doi:10.1016/j.healun.2012.09.011
  134. Lehmkuhl, 2009, Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in De Novo heart transplant recipients, Transplantation, 88, 115, 10.1097/TP.0b013e3181aacd22 · doi:10.1097/tp.0b013e3181aacd22
  135. Zuckermann, 2011, Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: a multicentre, randomized trial, J Transplant, 2011, 1, 10.1155/2011/535983 · doi:10.1155/2011/535983
  136. Andreassen, 2016, Everolimus initiation with early calcineurin inhibitor withdrawal in De Novo heart transplant recipients: three-year results from the randomized SCHEDULE study: early switch to everolimus after transplant, Am J Transplant, 16, 1238, 10.1111/ajt.13588 · doi:10.1111/ajt.13588
  137. Zuckermann, 2014, Sirolimus conversion after heart transplant: risk factors for acute rejection and predictors of renal function response: renal function after conversion to sirolimus, Am J Transplant, 14, 2048, 10.1111/ajt.12833 · doi:10.1111/ajt.12833
  138. West, 2019, Characteristics, risks, and outcomes of post-transplant lymphoproliferative disease >3 years after pediatric heart transplant: a multicenter analysis, Clin Transplant, 33, e13521, 10.1111/ctr.13521 · doi:10.1111/ctr.13521
  139. Chinnock, 2011, Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients: CNI minimization leads to improved renal function, Pediatr Transplant, 15, 746, 10.1111/j.1399-3046.2011.01566.x · doi:10.1111/j.1399-3046.2011.01566.x
  140. Asante-Korang, 2017, Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation, Clin Transplant, 31, e13054, 10.1111/ctr.13054 · doi:10.1111/ctr.13054
  141. Loar, 2013, Calcineurin inhibitor-free immunosuppression in pediatric heart transplantation recipients: sirolimus as a primary immunosuppressive agent, J Heart Lung Transplant, 32, S292, 10.1016/j.healun.2013.01.775 · doi:10.1016/j.healun.2013.01.775
  142. Schubert, 2014, Initial experience with CNI-free immunosuppression in pediatric heart transplant recipients - anticipating PTLD and chronic renal insufficiency, Thorac Cardiovasc Surg, 62, 10.1055/s-0034-1394000 · doi:10.1055/s-0034-1394000
  143. Tett, 2011, Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure, Transplant Rev (Orlando), 25, 47, 10.1016/j.trre.2010.06.001 · doi:10.1016/j.trre.2010.06.001
  144. Kniepeiss, 2011, The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation: CYP3A5 and dosing of tacrolimus and everolimus, Clin Transplant, 25, 146, 10.1111/j.1399-0012.2009.01198.x · doi:10.1111/j.1399-0012.2009.01198.x
  145. Arora, 2012, Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate, J Heart Lung Transplant, 31, 259, 10.1016/j.healun.2011.12.010 · doi:10.1016/j.healun.2011.12.010
  146. González-Vílchez, 2013, Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation, Clin Transplant, 27, E649, 10.1111/ctr.12241 · doi:10.1111/ctr.12241
  147. Rivinius, 2015, Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy, Drug Des Devel Ther, 9, 93
  148. Schober, 2013, Characteristics of early and late PTLD development in pediatric solid organ transplant recipients, Transplantation, 95, 240, 10.1097/TP.0b013e318277e344 · doi:10.1097/tp.0b013e318277e344
  149. Webber, 2006, Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study, Lancet North Am Ed, 367, 233, 10.1016/S0140-6736(06)67933-6 · doi:10.1016/s0140-6736(06)67933-6
  150. Tzani, 2021, Impact of induction therapy on outcomes after heart transplantation, Clin Transplant, 35, 10.1111/ctr.14440 · doi:10.1111/ctr.14440
  151. Nozohoor, 2020, Induction immunosuppression strategies and long-term outcomes after heart transplantation, Clin Transplant, 34, e13871, 10.1111/ctr.13871 · doi:10.1111/ctr.13871
  152. Truby, 2020, Impact of induction immunosuppression on post-transplant outcomes of patients bridged with contemporary left ventricular assist devices, ASAIO J, 66, 261, 10.1097/MAT.0000000000001119 · doi:10.1097/mat.0000000000001119
  153. Amin, 2019, Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era, Clin Transplant, 33, e13651, 10.1111/ctr.13651 · doi:10.1111/ctr.13651
  154. Castleberry, 2018, Risk stratification to determine the impact of induction therapy on survival, rejection and adverse events after pediatric heart transplant: a multi-institutional study, J Heart Lung Transplant, 37, 458, 10.1016/j.healun.2017.05.010 · doi:10.1016/j.healun.2017.05.010
  155. Butts, 2017, Effect of induction therapy on graft survival in primary pediatric heart transplantation: a propensity score analysis of the UNOS database, Transplantation, 101, 1228, 10.1097/TP.0000000000001285 · doi:10.1097/tp.0000000000001285
  156. Carlo, 2019, Comparison of 10-year graft failure rates after induction with basiliximab or anti-thymocyte globulin in pediatric heart transplant recipients—The influence of race, Pediatr Transplant, 23, 1, 10.1111/petr.13366 · doi:10.1111/petr.13366
  157. Ansari, 2016, Comparison of basiliximab and anti-thymocyte globulin as induction therapy in pediatric heart transplantation: a survival analysis, J Am Heart Assoc, 5, 1, 10.1161/JAHA.115.002790 · doi:10.1161/jaha.115.002790
  158. Butts, 2018, Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database, Pediatr Transplant, 22, 1, 10.1111/petr.13190 · doi:10.1111/petr.13190
  159. Grundy, 2009, Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation, J Heart Lung Transplant, 28, 1279, 10.1016/j.healun.2009.09.001 · doi:10.1016/j.healun.2009.09.001
  160. Morrow, 2012, Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients, Transplantation, 93, 319, 10.1097/TP.0b013e31823f7eea · doi:10.1097/tp.0b013e31823f7eea
  161. Schumacher, 2012, HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg, J Heart Lung Transplant, 31, 1041, 10.1016/j.healun.2012.05.009 · doi:10.1016/j.healun.2012.05.009
  162. Alloway, 2011, Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations, J Heart Lung Transplant, 30, 1003, 10.1016/j.healun.2011.02.008 · doi:10.1016/j.healun.2011.02.008
  163. Dressman, 1983, Stability of allopurinol and of five antineoplastics in suspension, Am J Health Syst Pharm, 40, 616, 10.1093/ajhp/40.4.616 · doi:10.1093/ajhp/40.4.616
  164. Elefante, 2006, Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels, Bone Marrow Transplant, 37, 781, 10.1038/sj.bmt.1705320 · doi:10.1038/sj.bmt.1705320
  165. Jacobson, 1997, Stability of tacrolimus in an extemporaneously compounded oral liquid, Am J Health Syst Pharm, 54, 178, 10.1093/ajhp/54.2.178 · doi:10.1093/ajhp/54.2.178
  166. Al Sagheer T, Enderby CY. Determining the conversion ratios for oral versus sublingual administration of tacrolimus in solid organ transplant recipients. Clin Transplant 2019;33:1-6. · doi:10.1111/ctr.13727
  167. Collin, 2010, Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study, Transplant Proc, 42, 4331, 10.1016/j.transproceed.2010.09.126 · doi:10.1016/j.transproceed.2010.09.126
  168. Doligalski, 2014, Sublingual administration of tacrolimus: current trends and available evidence, Pharmacotherapy, 34, 1209, 10.1002/phar.1492 · doi:10.1002/phar.1492
  169. Nasiri-Toosi, 2012, Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients, Exp Clin Transplant, 10, 586, 10.6002/ect.2012.0032 · doi:10.6002/ect.2012.0032
  170. Tsapepas, 2013, Sublingual tacrolimus: a pharmacokinetic evaluation pilot study, Pharmacotherapy, 33, 31, 10.1002/phar.1149 · doi:10.1002/phar.1149
  171. Watkins, 2012, Use of sublingual tacrolimus in lung transplant recipients, J Heart Lung Transplant, 31, 127, 10.1016/j.healun.2011.10.015 · doi:10.1016/j.healun.2011.10.015
  172. Reams, 2002, Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis, Am J Respir Med, 1, 91, 10.1007/BF03256598 · doi:10.1007/bf03256598
  173. Pennington, 2015, Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients, Am J Health Syst Pharm, 72, 277, 10.2146/ajhp140322 · doi:10.2146/ajhp140322
  174. Abu-Elmagd, 1991, Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation, Transplant Proc, 23, 2767
  175. Dhungel, 2012, 655 short-term outcomes in heart transplant recipients treated with generic tacrolimus, J Heart Lung Transplant, 31, S226, 10.1016/j.healun.2012.01.669 · doi:10.1016/j.healun.2012.01.669
  176. Kraeuter, 2013, Conversion to generic cyclosporine A in stable chronic patients after heart transplantation, Drug Des Devel Ther., 7, 1421
  177. Söderlund, 2015, Safety and efficacy of the switch to generic mycophenolate mofetil and tacrolimus in heart transplant patients, Clin Transplant, 29, 619, 10.1111/ctr.12564 · doi:10.1111/ctr.12564
  178. Spence, 2012, evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system, Pharmacotherapy, 32, 981, 10.1002/phar.1130 · doi:10.1002/phar.1130
  179. Khush, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match, J Heart Lung Transplant, 38, 1056, 10.1016/j.healun.2019.08.004 · DOI · Paper page
  180. Kiernan, 2019, Measuring alloantibodies: a matter of quantity and quality, Curr Opin Organ Transplant, 24, 20, 10.1097/MOT.0000000000000593 · doi:10.1097/mot.0000000000000593
  181. Loupy, 2016, Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection, Am J Transplant, 16, 111, 10.1111/ajt.13529 · doi:10.1111/ajt.13529
  182. Jain, 2019, Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation, Leuk Lymphoma, 60, 110, 10.1080/10428194.2018.1459603 · doi:10.1080/10428194.2018.1459603
  183. Fishbein, 2012, Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft, Hum Immunol, 73, 1213, 10.1016/j.humimm.2012.07.011 · doi:10.1016/j.humimm.2012.07.011
  184. Mokshagundam, 2020, Treatment and pattern of resolution of antibody-mediated rejection with hemodynamic compromise resistant to standard therapy after heart transplantation with a positive virtual crossmatch, J Heart Lung Transplant, 39, S458, 10.1016/j.healun.2020.01.299 · doi:10.1016/j.healun.2020.01.299
  185. Kobashigawa, 2011, Report from a consensus conference on antibody-mediated rejection in heart transplantation, J Heart Lung Transplant, 30, 252, 10.1016/j.healun.2010.11.003 · DOI · Paper page
  186. Wu, 2009, Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes, J Heart Lung Transplant, 28, 417, 10.1016/j.healun.2009.01.015 · doi:10.1016/j.healun.2009.01.015
  187. Kfoury, 2019, The impact of asymptomatic antibody-mediated rejection on outcome after heart transplantation, Curr Opin Organ Transplant, 24, 259, 10.1097/MOT.0000000000000640 · doi:10.1097/mot.0000000000000640
  188. Conway, 2012, Development of donor-specific isohemagglutinins following pediatric abo-incompatible heart transplantation: isohemagglutinins and heart transplant, Am J Transplant, 12, 888, 10.1111/j.1600-6143.2011.03910.x · doi:10.1111/j.1600-6143.2011.03910.x
  189. Chen, 2019, Donor-specific anti-HLA antibody production following pediatric ABO-incompatible heart transplantation, Pediatr Transplant, 23, e13332, 10.1111/petr.13332 · doi:10.1111/petr.13332
  190. Peled, 2017, The impact of gender mismatching on early and late outcomes following heart transplantation, ESC Heart Fail, 4, 31, 10.1002/ehf2.12107 · doi:10.1002/ehf2.12107
  191. Söderlund, 2017, Acute cellular rejection later than one year after heart transplantation: a single-center retrospective study at Skåne University Hospital in Lund 1988-2010, Clin Transplant, 31, e12998, 10.1111/ctr.12998 · doi:10.1111/ctr.12998
  192. Tran, 2016, Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation, J Heart Lung Transplant, 35, 87, 10.1016/j.healun.2015.08.008 · doi:10.1016/j.healun.2015.08.008
  193. Coutance, 2015, Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy, J Heart Lung Transplant, 34, 1050, 10.1016/j.healun.2015.03.002 · doi:10.1016/j.healun.2015.03.002
  194. Loupy, 2011, Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy: very late heart transplant rejection, Am J Transplant, 11, 1478, 10.1111/j.1600-6143.2011.03563.x · doi:10.1111/j.1600-6143.2011.03563.x
  195. Tible, 2013, Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation, J Heart Lung Transplant, 32, 769, 10.1016/j.healun.2013.05.012 · doi:10.1016/j.healun.2013.05.012
  196. Fenton, 2018, Comparative study of pediatric coronary allograft vasculopathy between single centers in North America and United Kingdom, Transplant Proc, 50, 3705, 10.1016/j.transproceed.2018.06.022 · doi:10.1016/j.transproceed.2018.06.022
  197. McGovern, 2019, Optical coherence tomography for the early detection of coronary vascular changes in children and adolescents after cardiac transplantation, JACC: Cardiovascular Imaging, 12, 2492
  198. Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. J Clin Microbiol 2018;56:1-6. · doi:10.1128/jcm.02009-17
  199. Baran, 2011, A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial, Circ: Heart Fail, 4, 129
  200. Baughman, 2012, Therapy for sarcoidosis: evidence-based recommendations, Expert Rev Clin Immunol, 8, 95, 10.1586/eci.11.84 · doi:10.1586/eci.11.84

200 of 385 shown

Cited by

See all 645

Metadata

Authors
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., Lavee, J., Pouch, S., Patel, J., Michaud, C., Shullo, M. A., Schubert, S., Angelini, A., Carlos, L., Mirabet, S., Patel, J., Pham, M., Urschel, S., Kim, K.-H., Miyamoto, S., Chih, S., Daly, K., Grossi, P., Jennings, D. L., Kim, I.-C., Lim, H. S., Miller, T., Potena, L., Velleca, A., Eisen, H., Bellumkonda, L., Danziger-Isakov, L., Dobbels, F., Harkess, M., Kim, D., Lyster, H., Peled, Y., & Reinhardt, Z.
Venue
The Journal of Heart and Lung Transplantation
Publisher
Elsevier BV
Published
2023-05
Volume
42
Issue
5
Pages
e1-e141
ISSN
1053-2498 (ISSN-L)
OpenAlex
W4313207390
Cited by
645
References
544
FWCI
102.37
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. https://app.cochat.ai/papers/10.1016/j.healun.2022.10.015
The paper
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., Lavee, J., Pouch, S., Patel, J., Michaud, C., Shullo, M. A., Schubert, S., Angelini, A., Carlos, L., Mirabet, S., . . . Reinhardt, Z. (2023). The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2022.10.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.